Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06925919 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Safety, Tolerability and Pharmacokinetics of IDB-011
A Phase 1 study of Rift Valley Fever, sponsored by IDBiologics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06925919 is a Phase 1 study of Rift Valley Fever that is actively recruiting participants, run by IDBiologics. The registered enrollment target is 40 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06925919, a Phase 1 study of Rift Valley Fever, is actively recruiting participants, sponsored by IDBiologics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase 1 randomized, double-blind, placebo-controlled trial to evaluate safety, tolerability, pharmacokinetics (PK) and immunogenicity of IDB-011 following intramuscular (IM )administration of single ascending doses to healthy adult participants.
Conditions Studied
Interventions
- DRUG IDB-011 dose level 1
- DRUG IDB-011 dose level 2
- DRUG IDB-011 dose level 3
- DRUG IDB-011 dose level 4
- DRUG IDB-011 dose level 5
Study Locations (1)
California
- Altasciences Clinical Los Angeles - Cypress
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-04-02 |
| Est. Completion | 2026-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06925919
The ClinicalTrials.gov registry entry for NCT06925919 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is IDBiologics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rift Valley Fever appearing as the primary indexed condition, and to 5 interventions - of which IDB-011 dose level 1 is the first listed.
NCT06925919 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06925919 about?
NCT06925919 is a clinical study titled "Study to Evaluate Safety, Tolerability and Pharmacokinetics of IDB-011". Phase 1 randomized, double-blind, placebo-controlled trial to evaluate safety, tolerability, pharmacokinetics (PK) and immunogenicity of IDB-011 following intramuscular (IM )administration of single ascending doses to healthy adult participants.
What is the current status of trial NCT06925919?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2025-04-02. Estimated completion is 2026-10.
What conditions does trial NCT06925919 study?
This clinical trial studies the following conditions: Rift Valley Fever.
What interventions are being tested in trial NCT06925919?
The interventions under investigation include: IDB-011 dose level 1 (DRUG), IDB-011 dose level 2 (DRUG), IDB-011 dose level 3 (DRUG), IDB-011 dose level 4 (DRUG), IDB-011 dose level 5 (DRUG).
Who is sponsoring clinical trial NCT06925919?
This trial is sponsored by IDBiologics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06925919 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rift Valley Fever
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.